23andMe is shutting down its therapeutics development division, and plans to seek out buyers to find a new home for its ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

After first claiming an FDA clearance last year for its mixed reality brain surgery navigation platform, Zeta Surgical has ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

During quarterly earnings calls across the medtech industry, a recurring question has been on investors’ minds: If ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...